- The FDA has approved Jazz Pharmaceuticals plc JAZZ Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in pediatric and adult patients.
- The approval covers the use of Rylaze as a component of a multi-agent chemotherapeutic regimen in patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase.
- The company expects Rylaze will be commercially available in mid-July.
- Price Action: JAZZ closed at $177.64 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
